Organon (OGN) Free Cash Flow (2020 - 2026)
Organon (OGN) posted quarterly Free Cash Flow of $65.0 million for Q2 2026, down 64.09% year-over-year from $181.0 million in Q2 2025, and down 65.43% on a QoQ basis from $188.0 million in Q1 2026.
Organon (OGN) Free Cash Flow (2020 - 2026) Analysis & Trends
Organon has reported Free Cash Flow for 7 years, with the latest figure at $65.0 million in Q2 2026.
- Free Cash Flow for Q2 2026 came in at $65.0 million, down 64.09% year-over-year; the trailing twelve-month figure through Jun 2026 was $567.0 million (down 13.83% YoY), and the FY2025 annual result was $538.0 million, down 29.58% from the prior year.
- Free Cash Flow slipped to $65.0 million in Q2 2026, from $188.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $335.0 million in Q4 2024 and troughed at -$44.0 million in Q2 2023.
- A 5-year average of $153.6 million and a median of $143.5 million in 2022 frame the typical range for Free Cash Flow.
- The widest annual swing landed in 2022, when Free Cash Flow surged 1800.0%; it then sank 141.51% in 2023.
- A 5-year view of Free Cash Flow shows it stood at $204.0 million in 2022, then surged by 55.88% to $318.0 million in 2023, then rose by 5.35% to $335.0 million in 2024, then sank by 71.34% to $96.0 million in 2025, then tumbled by 32.29% to $65.0 million in 2026.
- Per Business Quant data, the three most recent Free Cash Flow figures were $65.0 million in Q2 2026, $188.0 million in Q1 2026, and $96.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.56 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 302.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 440.07 Mn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 65.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.00 Mn |
| Jun 30, 2026 | 65.00 Mn |
| Mar 31, 2026 | 188.00 Mn |
| Mar 31, 2026 | 188.00 Mn |
| Dec 31, 2025 | 96.00 Mn |
| Dec 31, 2025 | 96.00 Mn |
| Sep 30, 2025 | 218.00 Mn |
| Sep 30, 2025 | 218.00 Mn |
| Jun 30, 2025 | 181.00 Mn |
| Jun 30, 2025 | 181.00 Mn |
| Mar 31, 2025 | 43.00 Mn |
| Mar 31, 2025 | 43.00 Mn |
| Dec 31, 2024 | 335.00 Mn |
| Dec 31, 2024 | 335.00 Mn |
| Sep 30, 2024 | 99.00 Mn |
| Sep 30, 2024 | 99.00 Mn |
| Jun 30, 2024 | 300.00 Mn |
| Jun 30, 2024 | 300.00 Mn |
| Mar 31, 2024 | 30.00 Mn |
| Mar 31, 2024 | 30.00 Mn |